Navigation Links
Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium

TAMPA, Fla., March 31, 2017 /PRNewswire/ -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has initiated first-in-human trials for its topoisomerase-1 inhibitor, IT-141, which encapsulates SN-38, the active metabolite of Pfizer's Camptosar® (irinotecan) and Merrimack Pharmaceuticals' Onivyde® (liposomal irinotecan), within a proprietary tumor-targeting micelle nanoparticle.

Unlike both Camptosar® and Onivyde®, IT-141 does not require metabolic generation of the active derivative, SN-38, delivering up to 50x more SN-38 to the tumor than Camptosar® in preclinical models. Despite inefficient delivery (less than 4% of irinotecan successfully converts into SN-38, of which only a fraction reaches the tumor), Camptosar® was one of Pfizer's blockbuster products, generating sales of more than $1 billion annually and remains on the World Health Organization (WHO) List of Essential Medicines.

Dr. Carolyn Paradise, Intezyne's Chief Medical Officer, stated, "We are excited to enter the clinic with IT-141, and I look forward to working closely with the investigators. Based on both the anti-tumor activity observed in established preclinical models and the potential safety advantages provided by Intezyne's proprietary tumor-targeting delivery technology, IT-141 has the potential to significantly improve patient outcomes across a wide variety of solid tumor indications where Camptosar® or Onivyde® are currently used."

On April 3, Intezyne's IT-139, a novel GRP78 inhibitor and the most clinically advanced GRP78 inhibitor in development for solid tumors, will be featured in an American Association for Cancer Research (AACR) symposium, "The Unfolded Protein Response in Tumor Biology: GRP78/BiP: Cancer's Comrade in Crime," presented by Dr. Amy S. Lee, PhD of the University of Southern California (USC). The Company's previously completed Phase 1 trial of IT-139 showed that it was well-tolerated, with manageable side effects, and successfully demonstrated anti-tumor activity in numerous tumor types. The 2017 AACR meeting will be attended by Mr. E. Russell McAllister, Intezyne's CFO, Dr. Paradise, and Dr. Suzanne Bakewell, Vice President and Program Manager for IT-139.

Mr. McAllister stated, "Having followed Intezyne's progress for the past few years, I was excited to join the management team last fall to help drive development of several potentially revolutionary therapeutic agents. GRP78 has been shown to play a significant role in tumor resistance and survival, and IT-139 has shown surprising synergy with existing anti-cancer agents, including checkpoint inhibitors. Consequently, after completing cGMP manufacturing in 2017, we intend to initiate one or more Phase 1b/2a studies in early 2018 to further explore these synergies."

"This is an exciting time for Intezyne as we continue to advance our lead product candidates. Our risk-mitigated development strategy requires that we aggressively strengthen the Company from both a financial and human capital standpoint," said Dr. Kevin Sill, Intezyne's Founder and CEO. "Russell brings tremendous development, financial and strategic expertise to Intezyne, and we expect that he will be instrumental in optimally positioning the Company for success as we move into mid-stage clinical studies for IT-139 and IT-141 and raise additional capital from investors."

For more information, please visit the Company's website at

E. Russell McAllister, CFO, (813) 910-2120

To view the original version on PR Newswire, visit:

SOURCE Intezyne Technologies, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Research and Markets - Global Gas Chromatograph Market to Grow at a CAGR of 5.2% by 2017-2021, with Agilent Technologies, PerkinElmer, Shimadzu & Thermo Fisher Scientific Leading the Way
2. BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
3. Global Oxygen Therapy Devices Market - Analysis, Technologies & Forecasts to 2021 - Rising Popularity of CPAP Devices - Research and Markets
4. E-Skin Ushers in the Next Era of Smart Technologies by Enabling the Shift from Wearables to Skin-worn Devices
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
6. Healthcare Stocks on Investors Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX Laboratories
7. Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
8. Global Antifungal Drugs Technologies and Markets Report 2017-2021 - Research and Markets
9. Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma
10. Palatin Technologies To Present At The 29th Annual ROTH Conference
11. Vertical-Cavity Surface-Emitting Lasers (VCSEL): Technologies and Global Markets
Post Your Comments:
(Date:7/2/2020)... ... July 02, 2020 , ... ScripHessco has ... Chiropractors Treat. , “From migraines to anxiety to fibromyalgia, chiropractors have proven ... the company. , Sourced from physician recommendations on WebMD, US News, and ...
(Date:7/1/2020)... ... July 01, 2020 , ... The final entry deadline for ... Tuesday, July 28. , The International Business Awards are widely considered to ... more than 4,000 nominations from organizations in more than 70 nations. , All ...
(Date:6/28/2020)... ... June 26, 2020 , ... Mediaplanet ... campaign brings together patients, healthcare providers, advocates, and scientists to spread awareness of ... for these devastating respiratory conditions. , More than 35 million Americans ...
Breaking Medicine Technology:
(Date:7/4/2020)... ... , ... Houston Life coach, Rashad Garrett, has thrown a lifeline to those ... his new app, Faith Of A Mustard Seed (FOAMS). , The global pandemic has ... In fact, a Federal Agency emergency helpline dedicated to helping people in emotional distress ...
(Date:7/2/2020)... ... July 02, 2020 , ... Allegheny Health Network (AHN) today announced that John ... (CMIO), effective immediately. Dr. Lee succeeds Robert White, MD, who announced his plans ... of the year to help support a seamless transition. , Dr. Lee joins AHN ...
(Date:7/1/2020)... ... July 01, 2020 , ... The ... Associate Professor of Medicine at the University of Massachusetts Medical School- Baystate and ... have joined the SIDM Board of Directors. Dr. Salvador and Ms. Gaffey’s service ...
(Date:6/28/2020)... ... June 26, 2020 , ... Recovery from drug and alcohol ... treatment center, proudly announces that it has reopened to serve new clients with ... a world affected by Covid-19. , When social-distancing guidelines changed the way residential ...
(Date:6/25/2020)... , ... June 25, 2020 , ... ... 2020 Best in KLAS Overall IT Services Firm, expanded its telehealth services ... , Led by seasoned telehealth expert and a Consulting Magazine “2020 Women Leaders ...
Breaking Medicine News(10 mins):